Genetic ablation of Sema3A, or pharmacological inhibition with a novel Sema3A inhibitory peptide, protected against diabetes-induced albuminuria, kidney fibrosis, inflammation, oxidative stress and renal dysfunction. Here, SEMA3A is linked to diabetes mellitus.